ReviewJournal of virology2026
Structures of New World mammarenavirus glycoproteins as targets for antibody-mediated neutralization.
Review in Journal of virology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
New World mammarenaviruses (NWMs) are viral pathogens endemic to the Americas, where several have acquired the capability for zoonotic transmission, leading to sporadic but potentially lethal viral hemorrhagic fever in humans. Several NWMs are classified as category A pathogens and are considered a persistent threat to human health due to their high case mortality rates, ability to spread through airborne transmission, and limited therapeutic and treatment options against them. Infection is mediated by the tripartite glycoprotein complex (GPC), which is the sole protein expressed on the viral envelope. The GPC, consisting of a receptor-binding domain (GP1), a fusion-enabling domain (GP2), and a stable signal peptide (SSP), governs viral entry initiated through the transferrin receptor 1 (TfR1). Subtle changes in GPC sequence and structure can drastically influence host range, immune recognition, and viral fitness, underscoring its central role in arenavirus pathogenicity and making it a prime target for therapeutic intervention. Over the past decade, advances in structural biology have enabled the elucidation of the molecular architecture of the NWM GPC and its interaction with host receptors and neutralizing antibodies. In this review, we discuss the information gleaned from structural interrogation of the NWM GPC and the significance of these findings on current therapeutic development against these lethal pathogens.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.